Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Paradigms of Cancer Require New Language: A Qualitative Study Exploring Language for Non-Curative Non-Palliative Cancer Surgery.

Journal of surgical oncology·2026
Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

ASO Visual Abstract: The Role of Adjuvant Primary Site Radiotherapy for Patients with Cutaneous Melanoma with Microsatellitosis.

Annals of surgical oncology·2026
Same author

The Role of Adjuvant Primary Site Radiotherapy for Cutaneous Melanoma Patients with Microsatellitosis.

Annals of surgical oncology·2026
Same author

Optimising patient centred drug development to realise impact.

Communications medicine·2026
Same author

Factors Associated with Time to Sarcoma Diagnosis: Results from a Global Cross-Sectional Survey by the Sarcoma Patient Advocacy Global Network (SPAGN).

Cancers·2026

Related Experiment Video

Updated: Jun 25, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K

What Is a Sarcoma 'Specialist Center'? Multidisciplinary Research Finds an Answer.

Roger Wilson1, Denise Reinke2, Gerard van Oortmerssen1

  • 1Sarcoma Patient Advocacy Global Network (SPAGN), 61200 Woelfersheim, Germany.

Cancers
|May 25, 2024
PubMed
Summary

Defining specialist sarcoma care is crucial globally. This study proposes core principles and features for expert sarcoma management, aiming to improve patient outcomes worldwide.

Keywords:
clinical expertiseexpert centerpatient advocacysarcomaspecialist center

More Related Videos

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.9K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K

Related Experiment Videos

Last Updated: Jun 25, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.6K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.9K
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K

Area of Science:

  • Oncology
  • Sarcoma Management
  • Healthcare Systems

Background:

  • Sarcoma treatment in specialist centers improves outcomes.
  • Global access to sarcoma expertise is limited, highlighting a need for defined standards.
  • Current definitions of 'specialist' or 'expert' centers are lacking.

Purpose of the Study:

  • To define specialist sarcoma care for patient advocates.
  • To provide a tool for healthcare providers to enhance sarcoma patient care.
  • To establish a framework for recognizing and developing sarcoma expertise globally.

Main Methods:

  • A discussion paper was developed for a workshop at the Sarcoma Patient Advocacy Group Network (SPAGN) 2023 Conference.
  • Expert input was gathered from 75 delegates and the Connective Tissue Oncology Society (CTOS).
  • Core Principles and supplementary Features for optimal sarcoma management were identified.

Main Results:

  • Identified the multi-disciplinary team discussion of every patient as the primary principle of specialist sarcoma care.
  • Outlined principles for accurate diagnosis, safe, high-quality treatment with curative intent.
  • Defined features encompassing healthcare areas, professional involvement, service provision, and R&D needs.

Conclusions:

  • Proposed the term 'Sarcoma Intelligent Specialist Network' to acknowledge expertise globally.
  • The framework allows for adaptation to national/local policies and budgets.
  • A foundation is established for further discussion and local refinement of sarcoma care standards.